Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis' KRAS Mutation Test Receives CE-IVD Mark

NEW YORK (GenomeWeb) – Biocartis today announced its Idylla KRAS Mutation Test has received CE-IVD marking. 

The Belgian company has launched the sample-to-result test for the detection of 21 relevant mutations in the KRAS oncogene. It is the first fully automated CE-IVD test available for routine use and detects all clinically relevant driver mutations of the KRAS oncogene in tissue of colorectal cancers at a 5 percent sensitivity rate, Biocartis said. 

According to the firm, the test is uniquely able to detect all relevant mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of the KRAS gene. It runs on Biocartis' PCR-based Idylla platform, which launched in September. The automated system is designed to work in any laboratory setting, enabling decentralized molecular testing, and generates result in between 40 minutes and 2.5 hours. 

Because formalin-fixed, paraffin-embedded tissue is inserted directly into the Idylla cartridge without the need for any pre-processing steps, the hands-on time required for the KRAS test is less than two minutes, Biocartis said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more